Simple Summary As the treatment advances, there were several novel agents developed for
R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and …

Background Little is known regarding the association of cetuximab treatment beyond
progression (TBP) with survival among patients with recurrent or metastatic head and neck …

Simple Summary To improve overall survival (OS), we evaluated a combination of
cetuximab and nivolumab for toxicity and efficacy in patients with incurable recurrent and/or …

Background Pembrolizumab alone or combined with chemotherapy is the standard of care
for first-line treatment of patients with recurrent or metastatic head and neck squamous cell …

Aim: Cetuximab was approved in 2008 for treating recurrent/metastatic (R/M) head-and-neck
squamous-cell carcinoma (HNSCC), and this study assessed the utilization of cetuximab for …

Background In patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …

Background The EXTREME protocol is the standard of care for recurrent or metastatic head
and neck squamous-cell carcinoma (R/M HNSCC) in first line. Beyond the first-line except …

Background The aims of this study are to evaluate the efficacy and safety of first-line
treatment with chemotherapy plus cetuximab in real-world patients with recurrent or …

Aim: Cetuximab combined with platinum is the standard first-line therapy in patients (pts)
with R/M SCCHN. DIRECT is the first multicenter prospective observational study evaluating …

Background After the introduction of ICI treatment, data about feasibility and activity of a
cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and …